AMGN

Amgen Inc. Common Stock Nasdaq Global Select
$240.96
Open: $239.87 High: $243.03 Low: $236.93 Close: $240.97
Range: 2021-06-23 - 2021-06-24
Volume: 2,342,936
Market: Open
Powered by Finage Stock APIDelayed data
AMGN
Amgen Inc. Common Stock One Amgen Center Drive Thousand Oaks CA, 91320-1799 http://www.amgen.com
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
  • CEO: Robert A. Bradway
  • Employees: 20,800
  • Sector: Healthcare
  • Industry: Biotechnology
AMGN News
Latest news about the AMGN
  • Amgen Announces Approval Of Aimovig® (Erenumab) In Japan For The Suppression Of Onset Of Migraine Attacks In Adults

    Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Aimovig® (erenumab) for the suppression of onset of migraine attacks in adults. Aimovig is the first and only approved treatment in Japan to block the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine.3 This is also the first independent submission and approval for Amgen K.K., a wholly owned affiliate of Amgen Inc.

    View More →
  • Here is What Hedge Funds Think About Amgen, Inc. (AMGN)

    Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]

    View More →
  • deCODE genetics: Predicting the probability of death

    Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts the time to all-cause death better than traditional risk factors.

    View More →
  • 2 Top Dividend Stocks You Can Buy and Hold Forever

    Dividend stocks can be a great source of passive income, and fortunately, there is no shortage of dividend-paying companies in the stock market. After all, many companies slash, or outright suspend, their dividends once the economy stops working in their favor. If you are looking for dividend stocks that can pay you for the rest of your life, rest assured: They exist.

    View More →
  • Acclaimed Makeup Artist Allan Avendaño Opens Up About Personal Skin Condition: Provides INSIDE LOOK At Life With Plaque Psoriasis

    Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with Allan Avendaño, makeup artist to Hollywood A-listers, for the INSIDE LOOK campaign to share his journey living with plaque psoriasis and the difficulties of being in his demanding role and dealing with a chronic skin condition. No stranger to the fast pace and demands of the entertainment industry, Avendaño knows that the show must go on no matter what obstacles, or plaques, arise—something many people living with plaque psoriasis

    View More →
  • Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 36% Undervaluation?

    Does the June share price for Amgen Inc. ( NASDAQ:AMGN ) reflect what it's really worth? Today, we will estimate the...

    View More →
  • Biogen gets FDA approval for Alzheimer's treatment

    Julie Hyman and Anjalee Khemlani breakdown what the FDA’s approval of Biogen’s Alzheimer’s drug will mean for the pharmaceutical industry as Biogen experienced a surge in shares and releases the cost of the treatment.

    View More →
  • Amgen's Sotorasib is First KRAS Inhibitor to Show Overall Survival Benefit in Lung Cancer With KRAS Mutations

    View more earnings on AMGNSee more from BenzingaClick here for options trades from BenzingaAmgen's Stomach Cancer Drug Acquired in Five Prime Buyout Extends Patients' Lives, Mid-Stage Study ShowsAmgen, Kyowa Kirin Ink .25B Deal for Developing KHK4083 In Skin Disorders© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Amgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference

    Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m. ET on Wednesday, June 9, 2021. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public

    View More →
  • Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data

    Amgen (NASDAQ: AMGN) today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical study for LUMAKRASTM (sotorasib) in previously treated patients with non-small cell lung cancer (NSCLC) during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. These data were also simultaneously published in the New England Journal of Medicine (NEJM). The publication includes mature overall survival and duration of response data, and re

    View More →
  • Amgen's Stomach Cancer Drug Acquired in Five Prime Buyout Extends Patients' Lives, Mid-Stage Study Shows

    Amgen Inc (NASDAQ: AMGN) has announced updated results for investigational bemarituzumab combined with chemotherapy from the Phase 2 FIGHT trial in patients with FGFR2b-positive, HER2-negative frontline advanced gastric or gastroesophageal junction cancers (GEJ). Bemarituzumab is the crown jewel of the Five Prime Therapeutics $1.9 billion buyout, which showed the treatment helped patients with advanced stomach cancer live longer. Patients taking the treatment and a chemotherapy combination lived

    View More →
  • Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers

    Amgen (NASDAQ:AMGN) today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial. The trial evaluated bemarituzumab plus chemotherapy (mFOLFOX6) versus chemotherapy alone in patients with FGFR2b-positive, HER2-negative frontline advanced gastric or gastroesophageal junction cancers (GEJ). New data includes median overall survival (OS), a secondary endpoint that was reached with longer follow-up, as well as additional analyses of

    View More →
  • This Is Why Amgen's New Cancer Drug Could Be Huge

    Biotechnology stocks are famous for dramatic price movements but smart investors have been eager to scoop up shares of Amgen (NASDAQ: AMGN) for a different reason. Despite its size, Amgen can move quickly where it matters most. On May 28, 2021, the FDA granted a highly accelerated approval to a new lung cancer therapy in record time.

    View More →
  • 15 Most Valuable Pharmaceutical Companies In The World

    In this article we are going to list the 15 most valuable pharmaceutical companies in the world. Click to skip ahead and jump to the 5 most valuable pharmaceutical companies in the world. There is no denying the impact that the global pharma industry has had in the world, and probably been responsible for the […]

    View More →
  • Amgen to Webcast Investor Meeting at ASCO 2021

    Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting at 4:00 p.m. ET on Friday, June 4, 2021. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will discuss clinical data being presented on the Company's recently FDA-approved KRASG12C inhibitor LUMAKRAS™ (sotorasib), anti-FGFR2b antibody bemarituzumab

    View More →
  • QIAGEN (QGEN) Launches Expanded Tissue CDx Kit for LUMAKRAS

    QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.

    View More →
  • Amgen (AMGN) Inks Deal With Kyowa Kirin to Develop AD Treatment

    Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.

    View More →
  • Dow Jones Today Leads, Stocks Climb As PMI Data Hits Record; Oil Prices Surge; AMC, Cloudera Lead Small Cap Rally

    ArcelorMittal and Devon Energy rallied, Boeing topped the Dow Jones today as stocks posted a strong start to the month of June.

    View More →
  • Amgen, Kyowa Kirin Ink $1.25B Deal for Developing KHK4083 In Skin Disorders

    Amgen Inc (NASDAQ: AMGN) and Kyowa Kirin Co Ltd (OTC: KYKOF) have agreed to jointly develop and commercialize KHK4083, Kyowa Kirin's Phase 3-ready anti-OX40 fully human monoclonal antibody in development for atopic dermatitis, with potential in other autoimmune diseases. In February, Kyowa Kirin announced positive results from a Phase 2 study of KHK4083 in patients with moderate-to-severe atopic dermatitis. In exchange for an upfront of $400 million and milestones worth up to $850 million, Amgen

    View More →
  • Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis

    Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody in development for the treatment of atopic dermatitis, with potential in other autoimmune diseases. In February, Kyowa Kirin announced positive results from a Phase 2 study of KHK4083 in patients with moderate-to-severe atopic dermatitis, which affects nearly 30 million people in major global markets1.

    View More →